Clinical Trial: BCMA CAR-T Plus LY3039478 Inhibitor in Multiple Myeloma

The use of CAR-T cell therapy is expanding in the treatment of multiple myeloma. Currently, several centers are producing their own CAR-T cell products. This clinical trial is open at the Fred Hutchinson Cancer Center.

This phase I trial determines the side effects and best dose of B-cell maturation antigen (BCMA)-chimeric antigen receptor (CAR) T-cells when combined with gamma-secretase inhibitor LY3039478, cyclophosphamide, and fludarabine in treating participants with multiple myeloma that that has come back or remains despite treatment.

Placing genes added in the laboratory into immune T-cells may make the T-cells recognize BCMA, a protein on the surface of cancer cells. LY3039478 may enhance the killing of cancer cells by increasing the BCMA expression on multiple myeloma cells, making the targeted BCMA CAR-T treatment more effective. LY3039478 also decreases the amount of BCMA found in the circulation (called soluble BCMA) that is not bound to the myeloma cells. LY3039478 can therefore reduce the potential for soluble BCMA to act as a decoy. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BCMA CAR T therapy with LY3039478, cyclophosphamide, and fludarabine may work better in treating participants with relapsed or persistent multiple myeloma.

Learn more about this clinical trial here:

Clinical Trial Information